Stock Track | Mirum Pharmaceuticals Soars 5.07% Intraday After Evercore Raises Price Target on Upcoming Trial Data

Stock Track03-05

Mirum Pharmaceuticals, Inc. (MIRM) saw its stock soar 5.07% during intraday trading on Wednesday, driven by positive analyst sentiment.

The surge follows Evercore ISI raising its price target on the stock to $126 from $101 and reiterating an "Outperform" rating. The analyst highlighted Mirum's growing rare-liver disease portfolio, upcoming data from multiple key trials, a clear competitive outlook, and a margin expansion story as key positives.

Specifically, the firm noted that Mirum expects mid-stage data for its experimental liver disease drug volixibat and interim late-stage data for its hepatitis D drug candidate brelovitug in the second quarter of 2026. Evercore also projects global peak sales of $1.2 billion for volixibat in treating primary sclerosing cholangitis, a rare chronic liver disease.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1109433891?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-05 03:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109433891","market":"us","top_or_hot":-1,"title":"Stock Track | Mirum Pharmaceuticals Soars 5.07% Intraday After Evercore Raises Price Target on Upcoming Trial Data","media":"Stock Track","content":"<p>Mirum Pharmaceuticals, Inc. (MIRM) saw its stock soar 5.07% during intraday trading on Wednesday, driven by positive analyst sentiment.</p><p>The surge follows Evercore ISI raising its price target on the stock to $126 from $101 and reiterating an \"Outperform\" rating. The analyst highlighted Mirum's growing rare-liver disease portfolio, upcoming data from multiple key trials, a clear competitive outlook, and a margin expansion story as key positives.</p><p>Specifically, the firm noted that Mirum expects mid-stage data for its experimental liver disease drug volixibat and interim late-stage data for its hepatitis D drug candidate brelovitug in the second quarter of 2026. Evercore also projects global peak sales of $1.2 billion for volixibat in treating primary sclerosing cholangitis, a rare chronic liver disease.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Mirum Pharmaceuticals Soars 5.07% Intraday After Evercore Raises Price Target on Upcoming Trial Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Mirum Pharmaceuticals Soars 5.07% Intraday After Evercore Raises Price Target on Upcoming Trial Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-03-05 03:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Mirum Pharmaceuticals, Inc. (MIRM) saw its stock soar 5.07% during intraday trading on Wednesday, driven by positive analyst sentiment.</p><p>The surge follows Evercore ISI raising its price target on the stock to $126 from $101 and reiterating an \"Outperform\" rating. The analyst highlighted Mirum's growing rare-liver disease portfolio, upcoming data from multiple key trials, a clear competitive outlook, and a margin expansion story as key positives.</p><p>Specifically, the firm noted that Mirum expects mid-stage data for its experimental liver disease drug volixibat and interim late-stage data for its hepatitis D drug candidate brelovitug in the second quarter of 2026. Evercore also projects global peak sales of $1.2 billion for volixibat in treating primary sclerosing cholangitis, a rare chronic liver disease.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MIRM","symbol_name":"Mirum Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1109433891","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109433891","pubTimestamp":1772651362,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Mirum Pharmaceuticals, Inc. (MIRM) saw its stock soar 5.07% during intraday trading on Wednesday, driven by positive analyst sentiment.The surge follows Evercore ISI raising its price target on the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MIRM":"Mirum Pharmaceuticals, Inc."},"translate_title":"个股追踪|Evercore因即将公布的试验数据上调目标价后，Mirum Pharmaceuticals盘中飙升5.07%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MIRM":1},"content_text":"Mirum Pharmaceuticals, Inc. (MIRM) saw its stock soar 5.07% during intraday trading on Wednesday, driven by positive analyst sentiment.The surge follows Evercore ISI raising its price target on the stock to $126 from $101 and reiterating an \"Outperform\" rating. The analyst highlighted Mirum's growing rare-liver disease portfolio, upcoming data from multiple key trials, a clear competitive outlook, and a margin expansion story as key positives.Specifically, the firm noted that Mirum expects mid-stage data for its experimental liver disease drug volixibat and interim late-stage data for its hepatitis D drug candidate brelovitug in the second quarter of 2026. Evercore also projects global peak sales of $1.2 billion for volixibat in treating primary sclerosing cholangitis, a rare chronic liver disease.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1109433891","isCrawlerRequest":true}